Journal of Molecular Neuroscience

, Volume 59, Issue 3, pp 343–350 | Cite as

SEPT14 Is Associated with a Reduced Risk for Parkinson’s Disease and Expressed in Human Brain

  • Liron Rozenkrantz
  • Ziv Gan-Or
  • Mali Gana-Weisz
  • Anat Mirelman
  • Nir Giladi
  • Anat Bar-Shira
  • Avi Orr-Urtreger


Genes involved in cytoskeletal stability and trafficking, such as MAPT and SNCA, are important risk factors for Parkinson’s disease (PD). Two members of the cytoskeletal Septin family, SEPT4 and SEPT5, were implicated in PD pathobiology. We aimed to determine whether Septin genes are associated with Parkinson’s disease. To this end, six SNPs located in four different Septin loci were analyzed in 720 PD patients and 740 controls, all of Ashkenazi–Jewish origin. In addition, SEPT14 was sequenced and its expression was determined in different human tissues. Our results revealed that two SNPs in the SEPT14 locus, rs11981883 and rs10241628, were associated with a reduced risk for PD (p = 0.02 and p = 0.005). A third SNP, rs77231105, was localized in the putative promoter of SEPT14 and was predicted to affect the binding of the transcription factor Nkx2.5. This SNP was also associated with a reduced risk for PD (OR = 0.28, p < 0.0007). The three SEPT14 SNPs defined a protective haplotype which significantly reduced the risk for PD by 4-fold (p = 0.002). SEPT14 was found to be expressed in the brain and in the Substantia Nigra. These results suggest that SEPT14 may have a protective role in Parkinson’s disease pathogenesis, yet more studies are necessary to validate these results.


Parkinson’s disease Septin 14 SEPT14 Genetics 



This work was supported by Tel Aviv Sourasky Medical Center Grant of Excellence, by the Kahn Foundation, by the Chief Scientist of the Israeli Ministry of Health (grant no. 3-4893), by the Legacy Heritage Biomedical Science Partnership Program of the Israel Science Foundation (grant no.1922/08). This work was performed in partial fulfillment of the requirements for an M.Sc. degree of Liron Rozenkrantz, Sackler Faculty of Medicine, Tel Aviv University, Israel.

Compliance with Ethical Standards

Conflict of Interest

All authors report no actual or potential conflict of interests.

Supplementary material

12031_2016_738_MOESM1_ESM.docx (233 kb)
ESM 1 (DOCX 233 kb)


  1. Ageta-Ishihara N, Miyata T, Ohshima C, et al. (2013) Septins promote dendrite and axon development by negatively regulating microtubule stability via HDAC6-mediated deacetylation. Nat Commun 4:2532CrossRefPubMedPubMedCentralGoogle Scholar
  2. Almeida MQ, Soares IC, Ribeiro TC, et al. (2010) Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults. J Clin Endocrinol Metab 95(3):1458–1462CrossRefPubMedGoogle Scholar
  3. Bland JM, Altman DG (2000) Statistics notes. The odds ratio. BMJ 320(7247):1468CrossRefPubMedPubMedCentralGoogle Scholar
  4. Checa M, Ruiz V, Montano M, Velazquez-Cruz R, Selman M, Pardo A (2008) MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet 124(5):465–472CrossRefPubMedGoogle Scholar
  5. Dawson TM, Dawson VL (2010) The role of parkin in familial and sporadic Parkinson’s disease. Mov Disord 25(Suppl 1):S32–S39CrossRefPubMedPubMedCentralGoogle Scholar
  6. Do CB, Tung JY, Dorfman E, et al. (2011) Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson’s disease. PLoS Genet 7(6):e1002141CrossRefPubMedPubMedCentralGoogle Scholar
  7. Estey MP, Kim MS, Trimble WS (2011) Septins. Curr Biol 21(10):R384–R387CrossRefPubMedGoogle Scholar
  8. Gan-Or Z, Bar-Shira A, Dahary D, et al. (2012) Association of sequence alterations in the putative promoter of RAB7L1 with a reduced parkinson disease risk. Arch Neurol 69(1):105–110CrossRefPubMedGoogle Scholar
  9. Gaunt TR, Rodriguez S, Day IN (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool ‘CubeX’. BMC Bioinf 8:428CrossRefGoogle Scholar
  10. Gilden J, Krummel MF (2010) Control of cortical rigidity by the cytoskeleton: emerging roles for septins. Cytoskeleton (Hoboken) 67(8):477–486Google Scholar
  11. Hall PA, Russell SE (2004) The pathobiology of the septin gene family. J Pathol 204(4):489–505CrossRefPubMedGoogle Scholar
  12. Hall PA, Jung K, Hillan KJ, Russell SE (2005) Expression profiling the human septin gene family. J Pathol 206(3):269–278CrossRefPubMedGoogle Scholar
  13. Heinemeyer T, Wingender E, Reuter I, et al. (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26(1):362–367CrossRefPubMedPubMedCentralGoogle Scholar
  14. Ihara M, Tomimoto H, Kitayama H, et al. (2003) Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson’s disease and other synucleinopathies. J Biol Chem 278(26):24095–24102CrossRefPubMedGoogle Scholar
  15. Ihara M, Yamasaki N, Hagiwara A, et al. (2007) Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 53(4):519–533CrossRefPubMedGoogle Scholar
  16. International Parkinson Disease Genomics, C., Nalls MA, Plagnol V, et al. (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377(9766):641–649CrossRefGoogle Scholar
  17. Keller MF, Saad M, Bras J, et al. (2012) Using genome-wide complex trait analysis to quantify ‘missing heritability’ in Parkinson’s disease. Hum Mol Genet 21(22):4996–5009CrossRefPubMedPubMedCentralGoogle Scholar
  18. Klein C, Westenberger A (2012) Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 2(1):a008888CrossRefPubMedPubMedCentralGoogle Scholar
  19. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI (2010) Tau protein: relevance to Parkinson’s disease. Int J Biochem Cell Biol 42(11):1775–1778CrossRefPubMedGoogle Scholar
  20. Lill CM, Roehr JT, McQueen MB, et al. (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: the PDGene database. PLoS Genet 8(3):e1002548CrossRefPubMedPubMedCentralGoogle Scholar
  21. Marttinen M, Kurkinen KM, Soininen H, Haapasalo A, Hiltunen M (2015) Synaptic dysfunction and septin protein family members in neurodegenerative diseases. Mol Neurodegener 10(1):16CrossRefPubMedPubMedCentralGoogle Scholar
  22. Matarasso N, Bar-Shira A, Rozovski U, Rosner S, Orr-Urtreger A (2007) Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate. Neoplasia 9(9):707–715CrossRefPubMedPubMedCentralGoogle Scholar
  23. Mostowy S, Cossart P (2012) Septins: the fourth component of the cytoskeleton. Nat Rev Mol Cell Biol 13(3):183–194PubMedGoogle Scholar
  24. Nemani VM, Lu W, Berge V, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1):66–79CrossRefPubMedPubMedCentralGoogle Scholar
  25. Pankratz N, Beecham GW, DeStefano AL, et al. (2012) Meta-analysis of Parkinson’s disease: identification of a novel locus, RIT2. Ann Neurol 71(3):370–384CrossRefPubMedPubMedCentralGoogle Scholar
  26. Parisiadou L, Cai H (2010) LRRK2 function on actin and microtubule dynamics in Parkinson disease. Commun Integr Biol 3(5):396–400CrossRefPubMedPubMedCentralGoogle Scholar
  27. Peterson EA, Kalikin LM, Steels JD, Estey MP, Trimble WS, Petty EM (2007) Characterization of a SEPT9 interacting protein, SEPT14, a novel testis-specific septin. Mamm Genome 18(11):796–807CrossRefPubMedGoogle Scholar
  28. Purcell S, Neale B, Todd-Brown K, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559–575CrossRefPubMedPubMedCentralGoogle Scholar
  29. Rodriguez S, Gaunt TR, Day IN (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169(4):505–514CrossRefPubMedPubMedCentralGoogle Scholar
  30. Russell SE, Hall PA (2011) Septin genomics: a road less travelled. Biol Chem 392(8–9):763–767PubMedGoogle Scholar
  31. Satake W, Nakabayashi Y, Mizuta I, et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 41(12):1303–1307CrossRefPubMedGoogle Scholar
  32. Shinoda T, Ito H, Sudo K, Iwamoto I, Morishita R, Nagata K (2010) Septin 14 is involved in cortical neuronal migration via interaction with septin 4. Mol Biol Cell 21(8):1324–1334CrossRefPubMedPubMedCentralGoogle Scholar
  33. Simon-Sanchez J, Schulte C, Bras JM, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41(12):1308–1312CrossRefPubMedPubMedCentralGoogle Scholar
  34. Son JH, Kawamata H, Yoo MS, et al. (2005) Neurotoxicity and behavioral deficits associated with septin 5 accumulation in dopaminergic neurons. J Neurochem 94(4):1040–1053CrossRefPubMedGoogle Scholar
  35. Tokhtaeva E, Capri J, Marcus EA, et al. (2015) Septin dynamics are essential for exocytosis. J Biol Chem 290(9):5280–5297CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Liron Rozenkrantz
    • 1
    • 2
  • Ziv Gan-Or
    • 1
    • 2
  • Mali Gana-Weisz
    • 1
  • Anat Mirelman
    • 3
  • Nir Giladi
    • 2
    • 3
  • Anat Bar-Shira
    • 1
  • Avi Orr-Urtreger
    • 1
    • 2
  1. 1.The Genetic InstituteTel-Aviv Sourasky Medical CenterTel AvivIsrael
  2. 2.Sackler Faculty of MedicineTel-Aviv UniversityTel-AvivIsrael
  3. 3.Movement Disorders Unit, Parkinson Center, Department of NeurologyTel-Aviv Sourasky Medical CenterTel-AvivIsrael

Personalised recommendations